RAPID MICRO BIOSYSTEMS, INC.
Close on Oct 19, 2026
- Market cap
- $37.40M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 6, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 7, 2026 | Before market open | $8.10M | $-0.27 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | $8.00M | $-0.31 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | Before market open | $11.30M | $-0.28 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 7, 2025 | Before market open | $7.80M | $-0.26 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | $7.30M | $-0.27 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | Before market open | $7.20M | $-0.26 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 28, 2025 | Before market open | $8.20M | $-0.22 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 1, 2024 | Before market open | $7.60M | $-0.26 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 2, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 3, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 1, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 7, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total gross margin percentage | full year 2026 | 20% | Maintained |
| Growth Direct system placements | full year 2026 | 30 to 38 | Maintained |
| system validation | full year 2026 | 27 | Lowered |
| total revenue | full year 2026 | $37.00M to $41.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Rapid Micro Biosystems filed with the SEC
Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct ® Platform
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Rapid Micro Biosystems Announces Record Preliminary Unaudited
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Dear RMB Team Members and Shareholders:
Other events · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Third Quarter 2024 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Second Quarter 2024 Financial Results
Results of operations · Listing notice · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter
Results of operations · Other events · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Guidance
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Announces Preliminary Unaudited
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Concludes Review of Strategic Alternatives
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Provides Business Update and Reports Second Quarter 2022 Financial Results
Material agreement · Results of operations · Exit or restructuring costs · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Rapid Micro Biosystems Announces Review of Strategic Alternatives to Maximize Shareholder Value
Material agreement · Results of operations · Exit or restructuring costs · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Rapid Micro Biosystems Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2021 Financial Results and Reaffirms Full Year 2022 Guidance
Results of operations · EX-99.1 to Form 8-K